BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to
examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous
intravenous (IV) infusion as monotherapy(treatment Arm 1) and in combination with
chemotherapy (treatment Arm 2) in patients with solid tumors.